BRIEF-S&P - Guatemala outlook revised to negative on higher fiscal pressures
* S&P - Guatemala outlook revised to negative on higher fiscal pressures; 'BB/B' foreign currency ratings affirmed
Dec 12 The Medicines Company said it will pay $105 million in an upfront payment for a two-year license to market Bristol-Myers Squibb Company's device to control bleeding during surgery.
The deal also gives Medicines Co the option to acquire the device, Recothrom, for a price based on average net sales during the two-year collaboration term.
The deal is expected to add to Medicines Co earnings per share in 2013, and add minimally to Bristol's earnings per share in 2013 and 2014, both companies said in a joint statement.
Medicines Co said in a separate statement that said it agreed to pay $185 million to acquire Redwood City, California-based Incline Therapeutics, which is developing a device to manage post-operative pain.
Medicines Co's shares closed at $21.85 on Tuesday on the Nasdaq.
Oct 28 S&P Global Ratings on Friday revised the sovereign credit outlook for Guatemala down to negative from stable, and affirmed its current BB/B foreign currency ratings.
BRASILIA, Oct 27 A Brazilian prosecutor investigating potentially corrupt investments made by state pension funds said the real estate company run by Republican presidential candidate Donald Trump appears to have benefited "suspiciously" from a massive redevelopment of Rio de Janeiro's port ahead of the Olympics.